DCGI gives greenlight to Covaxin phase 2,3 trials for 2 to 18 year-olds
Category: #headlines  By Mateen Dalal  Date: 2021-05-17
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

DCGI gives greenlight to Covaxin phase 2,3 trials for 2 to 18 year-olds

The DCGI (Drugs Controller General of India) has reportedly approved Hyderabad-based firm Bharat Biotech's proposal to conduct Phase 2 and 3 clinical trials of the COVID-19 vaccine, Covaxin, among children aged 2 to 18 years.

In the trial involving 525 healthy volunteers, the vaccine will be administered intramuscularly in two doses on day 0 and day 28, sources cited.

The Subject Expert Committee (SEC) reviewed the proposal on February 24 at a meeting, asking the company to submit a revised clinical trial protocol. Bharat Biotech's Covaxin, in association with the Indian Council of Medical Research (ICMR), is currently in use in India’s COVID-19 vaccination drive for adults.

For the record, apart from Covaxin, the Covishield vaccine from the Serum Institute of India (SII) is being used to vaccinate people in India.

The vaccine, backed by Russia's sovereign wealth fund, the Russian Direct Investment Fund (RDIF), has also obtained regulatory approval in India to manufacture and sell its vaccine Sputnik V. Indian multinational pharmaceutical firm, Dr. Reddy, will oversee its vaccine operations in the country.

Bharat Biotech and SII have put forth their four-month production plan to the DGCI as various states continue to report COVID-19 vaccine shortages. While Serum Institute claims it can raise production to 10 crore doses, Bharat Biotech said they could ramp up production to 7.8 crore doses by August.

It is worth noting that the company’s Covaxin reported a 78% efficiency rate against the COVID-19 virus in an early review of phase 3 clinical trials in April. Moreover, the vaccine is seen to effective against some of the fast-spreading strains that are infecting millions of Indians.

The Hyderabad-based company stated that the vaccine is 100% efficient against critical coronavirus disease, implying that those who receive it would not experience severe symptoms or need hospitalization.

Source Credit –

https://www.businesstoday.in/coronavirus/dcgi-nod-to-phase-23-clinical-trials-of-covaxin-in-age-group-of-2-18-years/story/438948.html

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

India could have 50 more startups with unicorn status in 2022: Report

India could have 50 more startups with unicorn status in 2022: Report

By Mateen Dalal

According to a report given by PwC India, the country has 50 startups that have shown potential to enter the prestigious unicorn club in 2022. By the end of this year, at least 100 new-age companies are expected to be valued above the USD 1 billion m...

U.S. records 1.35 Mn COVID-19 cases in a day, setting a global record

U.S. records 1.35 Mn COVID-19 cases in a day, setting a global record

By Mateen Dalal

The United States has recorded 1.35 million new Coronavirus cases, shattering global record of the highest daily total cases registered by any country in the world. The development comes amidst the widespread outbreak of the Omicron variant across th...

U.K. manufacturers predict enhanced output despite Brexit & inflation

U.K. manufacturers predict enhanced output despite Brexit & inflation

By Mateen Dalal

According to an industry study released recently, British manufacturers are quite optimistic that this year the business conditions and productivity is likely to improve, despite the fact that most have been affected by Brexit and rapid inflation. &...